[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-cognitive-impairment-mci-due-to-alzheimers-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-cognitive-impairment-mci-due-to-alzheimers-disease":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,71,99,131],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643954",false,"NCT07667478","NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for enrollment:\n\n* A clinical diagnosis of early AD, defined as either mild cognitive impairment (MCI) due to AD or mild dementia due to AD;\n* Evidence of cognitive impairment, characterized by a MMSE score between 20 and 28 and\u002For a CDR-Sum of Boxes score between 0.5 and 8, consistent with the contemporary definitions used in early AD in clinical trials; and\n* Biomarker confirmation of AD pathology, demonstrated by a positive plasma phosphorylated tau-217 (p-tau217) result according to the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic guidelines.\n\nExclusion Criteria:\n\n* Exclusion criteria include evidence of other neurological, psychiatric, or systemic conditions that could cause cognitive and functional impairments (e.g., substantial concomitant cerebrovascular disease, alcoholism, certain medications that could have a substantial effect on cognition, untreated major depressive disorder, and heart, renal or hepatic failure).\n* Individuals who have contraindications to receiving rTMS, including a history of seizures or any non-removable metal in their heads or within 12 inches of the TMS coil will be excluded.","ALL","55 Years","90 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD). The study will also evaluate the safety of this approach.\n\nThe main questions it aims to answer are:\n\n* Does rTMS applied to the cerebellum improve short-term memory in people with early AD?\n* How does this stimulation affect brain activity and connectivity measured by MRI?\n\nResearchers will compare active rTMS to sham rTMS (a look-alike procedure that does not deliver brain stimulation) to see if rTMS works to improve memory.\n\nParticipants will:\n\n* Complete a screening visit with medical and memory assessments\n* Be randomly assigned to receive either active rTMS or sham rTMS (neither participants nor researchers will know the assignment during treatment)\n* Receive 20 rTMS sessions over 4 weeks (about 20 to 30 minutes per session)\n* Undergo two MRI scans, one before and one after treatment\n* Complete memory and thinking tests and questionnaires at baseline, immediately after treatment, and at 3- and 6-month follow-up visits\n\nParticipation in the study will last about 6 months.\n\nThe rTMS is generally well tolerated. The most common side effects include mild headache and scalp discomfort during treatment, which are usually short-lasting. MRI is non-invasive and safe for most people. Study procedures will be reviewed to ensure participant safety.\n\nParticipants may or may not benefit directly from this study. People who receive active rTMS may experience improvement in memory. This research may help improve understanding of memory function in AD and support development of new treatments.",[25,26,27],"Alzheimer s Disease","Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease","Mild Dementia",[29,30,31],"Alzheimer's disease","Mild Cognitive Impairment","Mild dementia","RECRUITING","2026-06-24",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":36},"2026-04-15",{"date":40,"type":19},"2031-04-14",{"name":42,"class":43},"Chi-Ying (Roy) Lin","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":14,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100635488","NCT07553338","Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease","Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease","SALIENT-AD","Inclusion Criteria:\n\nPotential participants are required to meet all the following criteria for enrollment into the study:\n\n1. Adult males or females, 50 years of age and older\n2. Biomarker confirmed mild-to-moderate i.e., mild cognitive impairment\u002FAD (MCI\u002FAD) based on standard criteria (CDR 0.5 to 1.5).\n3. Cognition intact enough to participate in study procedures including cognitive testing (MoCA\\>11)\n4. Clinically normal resting 12-lead ECG at screening or, if abnormal, considered not clinically significant by the investigator\n5. Participant (or legally authorized representative) provides written informed consent prior to initiation of any study procedures\n6. Understands and agrees to comply with planned study procedures\n7. If receiving an FDA approved drug that treat the symptoms of AD (e.g., cholinesterase inhibitors and\u002For memantine) must be on a stable dose for at least 12 weeks prior to baseline\n8. If receiving an FDA approved drug that targets brain amyloid must be on a stable dose for at least 12 weeks prior to baseline\n9. If the participant is taking any supplement or medical food that may affect brain function must be on a stable dose or regimen for at least 12 weeks prior to baseline\n10. Participants on permitted concomitant medications should be on a stable dose of the permitted concomitant medication for at least 4 weeks unless a shorter duration is deemed acceptable by the investigator\n11. In the opinion of the investigator, have adequate cognition, literacy, vision, and hearing for neuropsychological testing\n12. The participant should have a study partner who can support the study participant and provide collateral information.\n\nExclusion Criteria:\n\nPotential participants meeting any of the following criteria will be excluded from enrolment into the study:\n\n1. Participant with a gene variation that would inhibit binding to the PET radiotracer (11C-DPA-713) and\u002For clinical factors that could affect PET signal, such as chronic use of benzodiazepines or NSAIDS\n2. Women who are pregnant or breastfeeding at screening or baseline\n3. Females of childbearing potential who within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following: (1) total abstinence, if it is their preferred and usual lifestyle; (2) an intrauterine device or intrauterine hormone-releasing system; (3) a contraceptive implant; (4) an oral contraceptive (with additional barrier method) with the participant being on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation; (5) have a vasectomized partner with confirmed azoospermia. Women who do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation shall be excluded. However, at the discretion of the investigator it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, i.e., double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical\u002Fvault cap with spermicide. NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).\n4. Male participants with female partners of childbearing potential are not eligible to participate if they do not agree to ONE of the following from the time prior to first dosing until 90 days after the last dose of study treatment: (1) are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; (2) Agree to use a male condom plus partner use of a contraceptive method with a failure rate of \\\u003C1% per year when having penile-vaginal intercourse with a partner of childbearing potential who is not currently pregnant. Men with a pregnant or breastfeeding partner are not eligible to participate if they do not agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration from the time prior to first dosing until 90 days after the last dose of study treatment\n5. Participants who are HIV positive at screening\n6. Participants with a past history (suspected or confirmed) of Hepatitis B should have HBsAg testing at screening and are excluded if HBsAg is positive\n7. Participants with a past history (suspected or confirmed) of Hepatitis C should have HCV RNA PCR testing at screening and are excluded if the HCV RNA PCR test is positive\n8. Presence based on exam, history or MRI of significant brain disease other than AD such as schizophrenia, epilepsy, Parkinson's disease or large territory stroke\n9. Current substance abuse in accord with Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria\n10. Significantly depressed (Geriatric Depression Scale \\> 10)\n11. Contraindications to MRI scanning, including claustrophobia, cardiac pacemaker\u002Fdefibrillator, ferromagnetic metal implants (e.g., in skull and cardiac devices other than those approved as safe for use in MRI scanners)\n12. Contraindications to PET\n13. Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG at screening or baseline which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety\n14. Any other medical conditions (e.g., cardiac, respiratory, gastrointestinal, or renal) which are not stable and\u002For adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments\n15. Participants with malignant neoplasms within 3 years of screening (except for basal or squamous cell carcinoma in situ of the skin or localized prostate cancer in male participants). Participants who had malignant neoplasms but who have had at least 3 years of documented uninterrupted remission before screening need not be excluded\n16. Participants who are participating in other interventional clinical trials that in the opinion of the investigator is likely to interfere with participation in or completion of the study or to affect study results or interpretation.\n17. Participants who were dosed in a clinical trial involving any new investigational drug for AD within 12 months prior to screening unless it can be documented that they received placebo\n18. Participants are not eligible if they have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab\n19. Participants who have previously received leronlimab\n20. Participants who are taking prohibited medications\n21. Inability for patient or proxy to provide informed consent or to comply with test requirements\n22. Visual or hearing impairment that, in the opinion of the investigator, would prevent the participant from performing psychometric tests accurately","50 Years",{"count":54,"type":19},20,[56],"PHASE2","The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certain types of cancer, its safety and tolerability in AD will be tested for the first time. The main purpose of this study is to learn:\n\n1. Is this drug safe for participants with AD and MCI due to AD?\n2. Does leronlimab change levels of brain inflammation?\n\nThe results of this study could lead to future studies with more participants that will test whether leronlimab may slow or prevent the decline in thinking abilities and brain function in this group of participants. Using leronlimab for Alzheimer's disease is experimental, which means that the Food and Drug Administration (FDA) has not approved leronlimab for this purpose.\n\nParticipants will be asked to take leronlimab once a week for 12 weeks in our clinic or in their own home. Participants will also be asked to complete the below procedures before and after taking leronlimab for 12 weeks:\n\n1. Undergo 2 types of brain scans, Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI).\n2. Visit our clinic for routine lab work, an electrocardiogram (ECG), and a physical exam.\n3. Donate blood so the researchers can better understand how leronlimab affects levels of inflammation and proteins related to AD in the blood.\n4. Undergo a series of tests and questionnaires that test thinking abilities.\n5. Have weekly phone calls with researchers to let them know if there are side effects while taking this drug.",[26,59],"Alzheimer's Disease",[59,30,61],"Clinical Trial","2026-05-19",{"date":64,"type":36},"2026-05-22",{"date":66,"type":36},"2026-04-30",{"date":68,"type":19},"2027-11",{"name":70,"class":43},"Weill Medical College of Cornell University",{"id":72,"slug":4,"hasResults":10,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":14,"minAge":52,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100563641","NCT06618807","Infrared Light for Memory Loss in Mild Cognitive Impairment (MCI)","A Pilot Study Evaluating the Feasibility, Safety, and Efficacy of the Neuro RX Gamma (Version 2) for the Treatment of Mild Cognitive Impairment (MCI)","PBMCI-Prime","Inclusion Criteria:\n\nIndividuals who meet the criteria for MCI of 1) cognitive concern by the subject, informant, or clinician; 2) Montreal Cognitive Assessment (MoCA) score between 19-25 and impairment in learning and memory domain; 3) essentially normal functional activities as derived from the Clinical Dementia Rating Scale (CDR) and 4) the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for MCI due to Alzheimer's disease. , Age is greater than or equal to 50 years old. Meets the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for MCI due to Alzheimer's disease.\n\nEssentially normal functional activities as derived from the CDR. If receiving ongoing cholinesterase inhibitor therapy and\u002For memantine, must be on a stable dosage for at least the prior 3 months.\n\nMoCA score between 19 and 25 at screening assessment and impairment in learning and memory domain.\n\nExclusion Criteria:\n\nCannot tolerate blood draws. Claustrophobia (fear of small or enclosed spaces), that cannot tolerate MRI scanners\\*.\n\nA pace-maker or other metal implants that would preclude safe use of MRI\\*. DSM 5 diagnosis of alcohol or other substance use disorders within the past 12 months.\n\nUnstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension).\n\nAny history of stroke, seizures, MS, or Lyme disease. Any issues with ambulation, vision, or hearing which could, in the opinion of the investigator, interfere with their ability to complete assessments.\n\nParticipant does not speak English at a level necessary for the completion of the assessments.\n\nHas not completed at least a grade eight education, as necessary for the completion of the assessments.\n\nCurrently participating in another clinical research study involving an investigational product.\n\nHistory of significant agitation and\u002For aggression, epileptic seizures. Current neurologic disease affecting cognition other than Alzheimer's disease. Photosensitivity reactions to sunlight or visible light (polymorphous light eruption, solar urticaria, persistent light reactivity).\n\nHistory of recurrent epistaxis within the last 24 weeks or currently taking major anti-coagulants (including warfarin, low molecular weight heparin) Increased skin sensitivity at the treatment site including active herpes simplex in the treatment area, history of keloid formation, or history of retinoid use in the past month.\n\nPregnant or lactating or planning to become pregnant. Currently undergoing infrared light therapy treatment. Any reason that, in the opinion of the investigator, might place a participant at unacceptable risk for participation in the trial.\n\nNote: \\*Participants with contraindications for MRI can still enroll in the trial and participate without undergoing the MRI procedure. However, if participants do not have contraindications, undergoing the MRI is required as part of the trial.",{"count":79,"type":19},60,[22],"Mild cognitive impairment (MCI) is a transitional risk state that occurs between the normal aging process and Alzheimer's dementia (AD). On average 32% of patients with MCI will progress to dementia, 62% will stay stable, and about 6% will return to normal cognition at subsequent visits.\n\nCurrent treatment for MCI includes cholinesterase inhibitors (donepezil, galantamine and rivastigmine), and NMDA receptor antagonists (memantine) which delay or slow the worsening of symptoms and treat cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning). Despite currently ongoing drug studies and modest clinical benefits of currently approved drug treatments, there continues to remain a need for treatments for long term symptomatic improvement of MCI with fewer and less severe side effects.\n\nPhotobiomodulation (PBM) therapy also called low-level laser (or light) therapy (LLLT) is a safe, non-invasive, non-thermal (no significant heat is generated) method of therapy which uses either visible red or near-infrared (NIR) light to stimulate, heal and repair damaged or dying tissue cells. This study proposes to use the Neuro RX Gamma device (version 2) to deliver NIR light energy to particular brain regions which are dysfunctional in MCI participants.",[26],[84,85,86,87,88,89],"photobiomodulation","light therapy","Alzheimer's Disease","clinical trial","Mild Cognitive Impairment (MCI)","home-based treatment","2025-11-27",{"date":92,"type":36},"2025-12-05",{"date":94,"type":36},"2025-01-10",{"date":96,"type":19},"2028-03-01",{"name":98,"class":43},"Unity Health Toronto",{"id":100,"slug":4,"hasResults":10,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":14,"minAge":52,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":20,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":44},"100577021","NCT06792877","Mindfulness for Cognition in Early-stage Alzheimer's Disease","Mechanisms of Mindfulness for Cognition in Early-Stage Alzheimer's Disease","Inclusion Criteria:\n\n* Healthy older adults will show cognitive performance within 1.0 SD for age \\& education adjusted norms on a neuropsychological test battery\n* Mild cognitive impairment (MCI) participants will show performance on delayed recall or one more or more other cognitive domains worse than 1.5 SD for age \\& education adjusted norms, an MMSE score between 25-30, and a MoCA score between 20-30.\n\nExclusion Criteria:\n\n* Participants without a computer, smart phone and internet access will be excluded\n* If they cannot understand the informed consent form or have moderate dementia.\n* Mood disorders (e.g., PTSD, depression, anxiety) or alcohol and drug use that either interferes with day-to-day life or required hospitalization within the past 5 years\n* Cerebrovascular disease\n* Any medical condition whose severity could significantly impair cognition (e.g., stroke, frontotermporal dementia, Parkinson's disease) are exclusionary",true,"100 Years",{"count":108,"type":19},100,[22],"The goal of this clinical trial is to learn if mindfulness meditation can improve outcomes in older adults with and without cognitive impairment. The main questions it aims to answer are:\n\n1. How does mindfulness impact thinking and memory?\n2. How does mindfulness influence brain function and structure?\n3. How does mindfulness affect daily function and quality of life?\n\nResearchers will compare all outcomes to one other groups. In one group, individuals will participate in a mindfulness class intervention; in the other group, individuals will not engage in any active interventions immediately, but will be placed on a waitlist for the mindfulness intervention. Researchers will compare all outcomes between the groups groups to determine whether the mindfulness interventions leads to greater improvement compared to no intervention (waitlist group).\n\nParticipants will:\n\n* Be randomly assigned to participate in the mindfulness intervention, or no immediate intervention (waitlist)\n* Complete paper-and-pencil cognitive testing, surveys, computerized tasks, and neuroimaging measures (EEG and MRI) before and after the intervention\n\nOutcomes will be assess at baseline, 2 months, 4 months and 6 months.",[88,26,112,113,114,115],"TBI (Traumatic Brain Injury)","Aging","Healthy Elderly","Alzheimer&Amp;Amp;#39;s Dementia (AD)",[117,113,88,118,119,120,121],"Mindfulness","Cognition","Memory","Alzheimers Disease","Social Group","2025-01-23",{"date":124,"type":36},"2025-01-27",{"date":122,"type":36},{"date":127,"type":19},"2027-03-31",{"name":129,"class":130},"VA Boston Healthcare System","FED",{"id":132,"slug":4,"hasResults":10,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":44},"100520566","NCT06058234","Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study","Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)","Inclusion Criteria:\n\n* Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.\n\nExclusion Criteria:\n\n* none",{"count":138,"type":19},8680,"OBSERVATIONAL","The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).",[142,26],"Mild Alzheimer's Disease","2023-09-21",{"date":145,"type":36},"2023-09-28",{"date":147,"type":36},"2023-07-06",{"date":149,"type":19},"2029-06-30",{"name":151,"class":130},"Centers for Medicare and Medicaid Services\u002F Coverage and Analysis Group",""]